AIB1蛋白在乳腺癌中的表达及在内分泌治疗中的临床意义  

The Expression of Nuclear Receptor Coactivators AIB1 in Breast Cancer and its Clinical Significance for Endocrine Therapy

作　　者：李庆霞[1] 潘海燕[1] 刑雅军[1] 张炎[1] 苗军程[1] 张秀智[1] 兰艳芹[1] 

机构地区：[1]河北省人民医院,河北石家庄050051

出　　处：《中国肿瘤》2012年第6期453-457,共5页China Cancer

基　　金：河北省科学技术厅基金(11276103D-70)

摘　　要：[目的]探讨AIB1在乳腺癌组织中的表达及其与乳腺癌内分泌治疗耐药及预后的关系。[方法]采用免疫组织化学方法检测120例乳腺癌组织、20例癌旁正常乳腺组织、40例良性乳腺病变组织中AIB1表达情况,并分析乳腺癌AIB1表达与乳腺癌内分泌治疗耐药及预后的关系。[结果]乳腺癌组织中AIB1过表达率(40.00%)显著高于正常乳腺组织(10.00%)和乳腺良性病变组织(15.00%)(P<0.05)。内分泌治疗耐药进展病例AIB1蛋白的阳性表达率明显高于内分泌治疗有效病例(60.00%vs27.00%,P<0.05)。[结论]AIB1高表达与乳腺癌内分泌治疗耐药密切相关,AIB1可以作为独立预测乳腺癌内分泌治疗疗效及预后的一个重要参数。[Purpose] To investigate the expression of nuclear receptor coactivators AIB1 in breast cancer,and the relationship of AIB1 expression with estrogen resistance during endocrine therapy and with prognosis of endocrine therapy. [Methods] The expression of AIB1 including 120 cases with breast cancer, 20 cases with normal breast and 40 cases with benign lesion was examined by immuno- histochemistry. The relationship of AIB1 expression with estrogen resistance and with prognosis of en- docrine therapy was analyzed. [Results] The over expression of AIB1 was 40.00% in breast can- cers,which was higher than that in benign lesions（15.00%） and in normal breast tissues（10.00%） with significant difference. The over expression rate of AIB1 in patiente with estrogen resistance （60.00%） was higher than that in the patients without recurrence or metastasis （27.00%）（P〈0.05）. [Conclusion]Over expression of AIB1 closely correlate to endocrine therapy. AIB1 may be as an independent mark- er for evaluating the efficacy and prognosis for endocrine therapy.

关 键 词：乳腺癌 AIB1蛋白 基因分型 内分泌耐药 

分 类 号：R737[医药卫生—肿瘤]